All In Biotech

Drug Trial Radar · NCT01769768

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Apr 2013

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on the PK of bupropion and warfarin patients with advanced solid tumors. Subjects will receive 800mg daily of LDE225 and two separate doses of either bupropion or warfarin.

Conditions

  • Advanced Solid Tumor

Interventions

  • LDE225Drug

    LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.

  • WafarinDrug

    15 mg single dose of warfarin (oral tablet) will be given to patients.

  • BupropionDrug

    75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) parameter AUClast for S- and R-warfarinTime frame: 7 days
  2. PK parameter AUClast for bupropionTime frame: 7 days
  3. PK parameter AUCinf for bupropionTime frame: 7 days
  4. PK parameter AUCinf for S- and R-warfarinTime frame: 7 days
  5. PK parameter Cmax for S- and R-warfarinTime frame: 7 days
  6. PK parameters Cmax for bupropionTime frame: 7 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center Oncology

    Duarte, California

  • University of Kansas Medical Center CBYM338B2203

    Kansas City, Kansas

  • Massachusetts General Hospital Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr

    Lebanon, New Hampshire

  • Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.

    Hackensack, New Jersey

  • University of Pennsylvania--Abramson Cancer Center Abramson Cancer Center

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Cancer Institute UPMC Cancer Pavilion

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina Dept.of Neurosciences/MS Ctr.

    Charleston, South Carolina

  • Cancer Centers of the Carolinas SC

    Greenville, South Carolina

  • Utah Health Science Center at San Antonio

    San Antonio, Texas

  • University of Utah / Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.